This is a long term medication taken every day and works over time, versus the immediate effects like Viagra. Other companies have abandoned this type of research and development in recent years, however the study published indicated there are some positive results forthcoming.
The focus here is that there not a place for a “pill in the bedroom” and rather it works long term. The company needs a shot in the arm with 2 of their major drugs coming off patent next year and there were the recent layoffs in the news too. BD
Boehringer Ingelheim Pharma Cuts 600-900 Drug Reps
Nov. 16 (Bloomberg) -- Boehringer Ingelheim GmbH’s desire pill, taken at bedtime for six months, boosted women’s libidos and led to better sex, according to the first published evidence showing the experimental drug works.
Women who took the medicine, known as flibanserin, reported 22 percent more “satisfying sexual events” than those given a placebo in two clinical tests of 1,378 patients, according to abstracts released today at the European Society for Sexual Medicine annual meeting in Lyon, France.
The findings show women who took the drug had more sex, wanted more sex and experienced less distress related to lack of desire. Boehringer plans to use the research to seek permission to sell the first female libido drug in the U.S. and Europe, potentially rekindling a debate that began a decade ago with the introduction of Pfizer Inc.’s Viagra on whether lackluster desire is a legitimate medical condition.
Some researchers and psychologists believe a pill has no place in the bedroom, and that women bothered by a decrease in desire should focus instead on the relationship and social factors that might explain the change.
Flibanserin is “not really an enhancement drug, like Viagra is -- taken on demand -- but a long-term treatment, like steroids,” New York psychologist Leonore Tiefer said by e-mail before the results were released.
The world’s largest closely held pharmaceutical company, Boehringer needs new drugs because it faces the loss of 1 billion euros ($1.5 billion) in annual revenue when two older medicines, Mirapex for Parkinson’s disease and Flomax to treat enlarged prostate, lose patent protection next year.
0 comments :
Post a Comment